Comparison
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
A metabolic disorder affecting neurotransmitter production, caused by deficiency of a specific enzyme. Requires careful dietary management and medication.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
0-1
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
metabolic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
metabolic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
6-pyruvoyl-tetrahydrobiopterin-synthase-deficiency-C0878676 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Neurologic onset | Often appears in infancy with abnormal tone or movement related to neurotransmitter disturbance. | Developmental delay may be noticed at a variable age and is not a specific metabolic crisis. | Moderate |
| Congenital features | Primary problem is biochemical rather than a characteristic pattern of congenital anomalies. | May include developmental disability and varied congenital features linked to missing 3q13 material. | Moderate |
| Metabolic clues | May be associated with abnormal phenylalanine or pterin-related testing; exact cutoffs are not stated here. | No specific metabolic marker is established by the supplied description. | High |
When to favor each condition
Choose 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 when
Infant with suspected neurotransmitter or phenylalanine disorder
The supplied description supports an enzyme deficiency affecting neurotransmitter production.
Moderate
Need for metabolic treatment planning
Dietary management and medication are described, but specific regimens must come from specialists.
Moderate
Biochemical testing is abnormal
An abnormal result may support evaluation for PTPS deficiency but does not alone confirm it.
High
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with congenital anomalies
The description links 3q13 deletion to developmental delay, intellectual disability, and congenital features.
Moderate
Suspected chromosomal cause
A chromosomal microarray or equivalent genetic test is more relevant than metabolic assays.
High
Variable-age presentation
Onset is described as variable rather than consistently in the first year.
Moderate
How key tests differ
| Test | 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Phenylalanine and pterin studies | May be abnormal; thresholds are not established here. | No characteristic abnormality is established. | Abnormal results need specialist confirmation and are not a diagnosis by themselves. |
| Neurotransmitter metabolite testing | May support a tetrahydrobiopterin-pathway disorder when interpreted clinically. | Not expected to identify the chromosomal deletion. | Use only within a metabolic evaluation; do not infer a definitive result. |
| Chromosomal microarray | Not the primary test for this enzyme deficiency. | May detect missing material at 3q13. | Genetic confirmation should be interpreted by a genetics clinician. |
Prognosis comparison
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
- Outcome
- Potentially severe chronic metabolic condition; individual outcome is not established here.
- Factors
- Recognition, specialist metabolic care, and response to management may influence course.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Generally described as moderate but chronic, with variable developmental impact.
- Factors
- Extent of deleted material, associated anomalies, and support services may affect outcome.
Time frame: Both are long-term conditions; precise timelines are not established.
Do not infer survival, prevalence, or treatment response from this comparison.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopment | Severe metabolic disturbance may affect neurologic function if not recognized. Intellectual disability and developmental delay are described features. Severity and outcomes vary; no mortality estimate is established. |
| Treatment burden | May require ongoing diet and medication under specialist care. Care is mainly developmental, educational, and supportive rather than dietary. Exact treatments and doses are not provided. |
| Associated anomalies | No specific congenital anomaly pattern is established here. Various congenital features may occur, but their frequency is not stated. Individual assessment is required. |
Patient education highlights
- HighSpecialist confirmation
Neither label should be assigned from symptoms alone; metabolic or genetic confirmation and clinician review are needed.
- HighDifferent care pathways
PTPS deficiency centers on metabolic management, while 3q13 deletion centers on developmental and congenital care.
- MediumInheritance counseling
Families should discuss recurrence risk with a genetics professional; transmission details are not established here.